Politics & Law
Purge at the CDC: How RFK Jr.’s Vaccine Shake-Up Opens a New Front in America’s Culture War
Seventeen careers ended with a single memo—an unprecedented eviction notice that turned a sleepy bureaucratic panel into the hottest battleground...
Read more
Carbon Shadows: How Invisible Soot Is Reshaping COPD Diagnosis and Environmental Policy
Under the microscope, the macrophage looks like a lunar eclipse—its cytoplasm eclipsed by a dark halo of carbon so dense...
Read more
From Crisis to Controversy: How States Are Allocating Their $50 Billion Opioid Settlement
When billions of dollars flow into state budgets, decisions about allocation quickly transcend fiscal planning—they become moral judgments. This reality...
Read more
Beyond Labels: The Policy Battle Brewing Over Ultra-Processed Foods
On a crisp May morning at the Axios Future of Health Summit, an audience of nutritionists, policymakers, and influencers erupted...
Read more
Compound Controversy: The FDA’s Political Tug-of-War Over Ozempic and Wegovy Alternatives
In early May 2025, countless Americans awoke to unsettling news—this time not about a virus, but about access to vital...
Read more
Mpox Reemerges in Africa: The Viral Threat Amid Vaccine Shortages and Political Abandonment
In a bustling hospital in Addis Ababa, Ethiopia, patients queue anxiously, nurses rush between packed wards, and health officials tally...
Read more
Bird Flu and Bureaucracy: How Political Maneuvering Threatens America’s Pandemic Preparedness
When public health collides with politics, the resulting reverberations can jeopardize entire populations. On a bleak morning this May, dairy...
Read more
A Pact Amidst Power Plays: The WHO’s Pandemic Agreement and the Fragile Balance Between Sovereignty and Solidarity
In a historic moment steeped in symbolism and surrounded by palpable tension, the World Health Organization (WHO) adopted its first-ever...
Read more
Cleared for Breath, Clouded in Doubt: The Political Economy Behind the FDA’s Approval of Nucala for COPD
Hope often comes with a disclaimer. That was the unspoken sentiment last week when the U.S. Food and Drug Administration...
Read more
More Than a Pop Star Problem: Miley Cyrus, Ovarian Cysts, and the Silence Around Gynecological Pain
It wasn’t a red carpet moment, but it made headlines just the same. In a candid interview, pop icon Miley...
Read more
Pharmaceutical Power and the Fight for Reform: Untangling the Complex Web of U.S. Drug Pricing
Few corners of the U.S. healthcare system are as opaque—or as fiercely contested—as the terrain of drug pricing. This spring,...
Read more
The WHO Pandemic Treaty Debate: Global Unity or Sovereign Resistance?
As memories of COVID-19's global chaos linger, the international community is grappling with an ambitious yet polarizing idea: a legally...
Read more
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more